A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

November 20, 2023

Primary Completion Date

January 30, 2027

Study Completion Date

October 10, 2030

Conditions
Relapsed or Refractory T-cell Lymphomas
Interventions
DRUG

BMS-986369

Specified dose on specified days

Trial Locations (40)

7348551

RECRUITING

Hiroshima University Hospital, Hiroshima

446-8602

RECRUITING

Anjo Kosei Hospital, Anjo-shi

467-8602

RECRUITING

Nagoya City University Hospital, Nagoya

441-8570

RECRUITING

Toyohashi Municipal Hospital, Toyohashi

296-0041

RECRUITING

Kameda General Hospital, Kamogawa

277-8577

RECRUITING

National Cancer Center Hospital East, Kashiwa

286-8520

RECRUITING

International University of Health and Welfare Narita Hospital, Narita

820-8505

RECRUITING

Aso Iizuka Hospital, Iizuka

806-8501

RECRUITING

Japan Community Healthcare Organization Kyushu Hospital, Kitakyushu-shi

0608648

RECRUITING

Hokkaido University Hospital, Sapporo

660-8550

RECRUITING

Hyogo Prefectural Amagasaki General Medical Center, Amagasaki

650-0047

RECRUITING

Kobe City Medical Center General Hospital, Kobe

259-1193

RECRUITING

Tokai University Hospital, Isehara

238-8558

RECRUITING

Yokosukakyosai, Yokosuka

980-8574

RECRUITING

Tohoku University Hospital, Sendai

856-8562

RECRUITING

National Hospital Organization Nagasaki Medical Center, Ōmura

857-8511

RECRUITING

Sasebo City General Hospital, Sasebo

589-8511

RECRUITING

Kindai University Hospital- Osakasayama Campus, Ōsaka-sayama

350-1298

RECRUITING

Saitama Medical University International Medical Center, Hidaka

104-0045

RECRUITING

National Cancer Center Hospital, Chuo-ku

173-8610

RECRUITING

Nihon University Itabashi Hospital, Itabashiku

135-8550

RECRUITING

Japanese Foundation for Cancer Research, Koto

105-8471

RECRUITING

The Jikei University Hospital, Minato-ku

810-8563

RECRUITING

National Hospital Organization Kyushu Medical Center, Fukuoka

812-8582

RECRUITING

Kyushu University Hospital, Fukuoka

814-0180

RECRUITING

Fukuoka University Hospital, Fukuoka

730-0052

RECRUITING

Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Hiroshima

890-0064

RECRUITING

Imamura General Hospital, Kagoshima

890-8520

RECRUITING

Kagoshima University Hospital, Kagoshima

860-0008

RECRUITING

National Hospital Organization Kumamoto Medical Center, Kumamoto

860-8556

RECRUITING

Kumamoto University, Kumamoto

602-8566

RECRUITING

University Hospital,Kyoto Prefectural University of Medicine, Kyoto

181-8611

RECRUITING

Kyorin University Hospital, Mitaka

889-1692

RECRUITING

University of Miyazaki Hospital, Miyazaki

852-8104

RECRUITING

The Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki

700-8558

RECRUITING

Okayama University Hospital, Okayama

904-2195

RECRUITING

Nakagami Hospital Okinawa, Okinawa

541-8567

RECRUITING

Osaka International Cancer Institute, Osaka

545-8586

RECRUITING

Osaka Metropolitan University Hospital, Osaka

870-8511

RECRUITING

Oita Prefectural Hospital, Ōita

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT06035497 - A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3) | Biotech Hunter | Biotech Hunter